Geron's First Profit Since 2015 Got A Boost From A Smaller Returns Reserve
Geron posted $1.4 million in quarterly net income as a cut to its returns reserve trimmed deductions from sales.
Geron, the biopharmaceutical company that sells the blood-cancer drug RYTELO, reported net income of $1.4 million for the third quarter, its first profit since 2015 apart from that quarter, according to its 10-Q. The same filing shows a cut to the product-returns reserve ahead of a new policy that sharply limits returns, which lowered the deductions taken from gross sales.
A returns reserve that shrank
Net product revenue was $60.1 million, against $47.2 million a year earlier. The sales-returns line, normally a deduction, flipped to a $33 thousand credit from a $1.8 million charge in the third quarter of 2025.
The 10-Q says that effective November 1, 2026, Geron revised its returned goods policy to "significantly limit the circumstances under which customers may return" product. Anticipating fewer returns, the company shrank its reserve for them during the quarter, so deductions from gross sales fell.
Total deductions were 19.3% of gross product revenue, compared with 21.6% a year earlier and 20.7% in the prior quarter's filing. Geron expects them to land in the low-to-mid-twenties percent range in the fourth quarter. The filing also credits higher sales volume, from more accounts and patients on therapy, for the revenue gain.
Costs: lower spending, bigger write-offs
Operating income was $5.8 million, versus a $13.9 million loss a year earlier. Research and development fell to $12.7 million from $21.1 million, and selling, general and administrative costs to $35.7 million from $39.0 million, both helped by a December 2025 workforce cut of roughly one-third.
Cost of goods sold rose to $6.1 million from $1.0 million, with non-cash inventory write-offs of $4.8 million driving much of the increase. Interest expense was $7.2 million. Cash and securities stood at $339.4 million at September 30.
One drug, one indication
Geron announced in October that it was ending its Phase 3 IMpactMF trial in relapsed or refractory myelofibrosis, after an independent data monitoring committee concluded the trial was unlikely to meet its main goal of overall survival, per an 8-K filed October 28. The 10-Q says Geron will not recoup its investment there and will stay "wholly dependent" on RYTELO in lower-risk myelodysplastic syndromes.
RYTELO launched in the US in June 2024 and won European Commission approval in March 2025. Geron has started a gated rollout in Europe; Germany should get the drug by the end of 2026, and France in 2027.
The Pharmakon loan's extra Tranche B and C tranches, $75.0 million and $50.0 million, expired undrawn, leaving the $125.0 million Tranche A loan, which matures November 1, 2029. Geron's market value was $598 million as of Wednesday's report.
The fourth-quarter report will show whether deductions climb into the low-to-mid-twenties range Geron guided to now that the new returns policy is in force.
Sources
- 10-Q Filing — Geron (GERN) — SEC EDGAR
- 10-Q Filing — Geron (GERN), Q2 FY2026 filed 2026-08-05 (comparison basis) — SEC EDGAR
- 8-K Filing — Geron, filed 2026-10-28 (Items 8.01, 9.01) — SEC EDGAR
- Earnings release (8-K Item 2.02, d188608dex991.htm) — Geron, filed 2026-11-04 — SEC EDGAR
- Geron (GERN) Reports Break-Even Earnings for Q3 — Yahoo Finance
- Geron outlines $220M-$240M 2026 RYTELO net revenue outlook while initiating Germany launch by year-end (NASDAQ:GERN) — seekingalpha.com
- Geron stock gains after Q3 2026 results (GERN:NASDAQ) | Seeking Alpha — seekingalpha.com
- Geron Corporation Q3 2026 Earnings Call Summary — Yahoo Finance
- Geron Q3 2026 Earnings Call Transcript — benzinga.com